Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Monoamine neurotransmitter balance (dopamine, norepinephrine, 5-HT)

Monoamine Balance & Synthesis · Neurotransmission and synaptic plasticity

Supplies aromatic amino acid precursors, or mildly modulates MAO enzyme activity and transporters, supporting steady release of dopamine, norepinephrine and serotonin.

Why it matters: Regulates motivation, drive, mood, reward pathways and neuropsychological resilience against depression and anxiety.

Molecular targets: Tyrosine Hydroxylase (TH), Aromatic L-amino Acid Decarboxylase, MAO-A/B, SERT/DAT

Supplements acting on this mechanism (ranked by strength and evidence)

5-HTP

★★★★★Mechanism evidence: grade A

5-HTP is converted directly to 5-hydroxytryptamine (serotonin) by aromatic amino acid decarboxylase, bypassing tryptophan hydroxylase, the rate-limiting step. There is human evidence for this precursor role. But serotonin is stored in intracellular vesicles, so this does not mean the synaptic cleft is directly filled. A rise in urinary 5-HIAA mainly reflects peripheral metabolism and does not prove that brain serotonin increased.

L-tyrosine

★★★★☆Mechanism evidence: grade B

Tyrosine is a precursor for dopamine and noradrenaline synthesis, and human metabolic markers support this role. However, tyrosine hydroxylation is the main rate-limiting step. The doses used in the studies above were typically above 0.5–2 g/day. There is no guarantee that usual doses increase central neurotransmitter release, and evidence for cognitive improvement under stress is also insufficient.

Pyridoxal 5’-phosphate (active vitamin B6)

★★★★☆Mechanism evidence: grade B

PLP is the coenzyme for aromatic amino acid decarboxylase, which decarboxylates levodopa and 5-HTP to make dopamine and serotonin. The enzyme’s mechanism is well defined, and human studies of inherited defects support it. Whether routine supplementation increases central monoamine release in well-nourished people has not been confirmed.

Methylene blue (USP pharmaceutical grade)

★★★★☆Mechanism evidence: grade B

Methylene blue is a potent MAO-A inhibitor, with a Ki of about 27 nmol/L in purified enzyme experiments. Increases in synaptic neurotransmitters in humans have not been measured directly, but drug labeling already warns of serotonin syndrome risk when it is combined with serotonergic drugs.

Citicoline

★★★☆☆Mechanism evidence: grade C

In animal studies, rats given 300 mg/kg by intraperitoneal injection had higher striatal dopamine content, and striatal tyrosine hydroxylase activity also changed. This suggests dopamine metabolism may shift. These results come from animals, and the dose and route differ from usual oral dosing. There is still no reliable target validation in humans.

Bacopa monnieri extract (bacosides)

★★★☆☆Mechanism evidence: grade C

In young rats, expression of tryptophan hydroxylase-2 and the serotonin transporter in the hippocampus changed. That does not prove that serotonin release increases in the adult brain. A human randomized trial found no significant change in monoamine oxidase activity, and there is no human evidence yet for an anti-anxiety effect.

Polygala tenuifolia extract

★★★☆☆Mechanism evidence: grade C

Animal experiments suggest Polygala can alter brain monoamine-related metabolism. In vitro, some Polygala oligosaccharide esters inhibit norepinephrine transport only at micromolar concentrations, and the claim that they inhibit all three transporters at once lacks human evidence.

High-concentration Peruvian maca extract (macaenes and macamides)

★★★☆☆Mechanism evidence: grade C

In animal studies, high doses of maca petroleum ether extract increased dopamine and norepinephrine in brain tissue. Macamides can inhibit FAAH in cell-free assays, but FAAH is an endocannabinoid-metabolizing enzyme, not a monoamine target. Neither a dopamine effect nor a CB1 effect has been confirmed in humans.

L-theanine

★★☆☆☆Mechanism evidence: grade C

In animal studies, L-theanine changed monoamine levels in brain regions and striatal dopamine release, with the direction varying by model and neurotransmitter. Central monoamine release after usual oral doses has not been directly verified in humans, so the relevance of this effect to people is unclear.

Agmatine sulfate

★★☆☆☆Mechanism evidence: grade C

In rats, injected agmatine altered the firing of 5-HT neurons in the dorsal raphe nucleus and the expression of related receptors. But injection differs from oral supplementation, and effects at α2 and imidazoline receptors cannot be directly equated with regulation of monoamine synthesis or transport. Human effects are unknown.

Uridine monophosphate (UMP)

★★☆☆☆Mechanism evidence: grade C

Some animal studies suggest uridine-related substances affect dopamine transmission in the striatum, and some of these results came from UMP combined with DHA. The direction of change in dopamine receptor density and its significance in humans are not established, so it cannot be concluded that UMP alone improves human motivation or receptor sensitivity.

Rhodiola rosea extract

★☆☆☆☆Mechanism evidence: grade D

Rhodiola extract and its components showed inhibitory activity in a recombinant human MAO system, an in-vitro result. Extract composition and pharmacokinetics vary considerably, and in-vitro inhibition does not show that effective concentrations are reached in the brain. There is also no reliable evidence that usual oral doses inhibit MAO in the human brain or change monoamine turnover.

NADH

★☆☆☆☆Mechanism evidence: grade D

NADH takes part in the endogenous BH4 reduction cycle, a known biochemical reaction, but this does not mean that oral supplementation produces the same effect. No human study has shown that usual oral NADH increases brain BH4 regeneration, tyrosine hydroxylase activity, or synaptic dopamine.

Open in the interactive app ›